07:39 AM EDT, 06/20/2024 (MT Newswires) -- AstraZeneca ( AZN ) said Thursday that its breast cancer drug Truqap in combination with Faslodex has been approved by the European Commission to treat adults with locally advanced or metastatic estrogen receptor (ER)-positive HER2-negative breast cancer.

The approval followed the positive opinion of the Committee for Medicinal Products for Human Use based on the results of a phase 3 trial showing the combination therapy cut the risk of disease progression or death by 50% compared with Faslodex alone, according to AstraZeneca ( AZN ).

With the approval, Astex Therapeutics is now able to receive a milestone payment from AstraZeneca ( AZN ) on the first commercial sale of the drug in the EU, as well as royalties on future sales, AstraZeneca ( AZN ) said.

The Truqap and Faslodex combination therapy is also approved for similar indications in the US and Japan, the company said.

Price: 78.59, Change: +0.17, Percent Change: +0.22